We have seen a flood of Biotech companies which are seeking to or have now raised capital through an IPO. Looking back at 2020, the sector recorded more than 100 IPOs globally which is almost double compared to 2019 numbers with the Biotech sector fund raising scaled, public markets continue to be the driver of this strong performance.
We are excited to introduce you to our panel of Biotech-Entrepreneurs who will share their journey from seeding to listing a biotech life sciences company on the stock exchange and why a record number of biotechs are going public.
We have a very strong panel this week, with @Sharon Shacham, CSO and Co-founder @ Karyopharm Therapeutics Inc (NASDAQ: KPTI). She bootstrapped a Karyopharm in 2008 with a drug that she designed for the treatment of solid tumours to treat Cancer Patients. There are very few peo
Sarah Howell, CEO @ Arecor Therapeutics plc (LSE:AREC), a globally focused biopharmaceutical company that is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. Arecor raised over £20mn in its IPO round and made a stunning bow on London’s AIM market with a market cap of £62.5mn. Then its share price immediately grew wings as its market cap soared to £116mn after the IPO.
Peter Rands, CEO and Co-founder @ Small Pharma Inc. (TSXV:DMT), a London based neuropharmaceutical company specialised in IP led development of novel treatments for mental health conditions - with a focus on depression, listed on the Canadian Toronto Venture Stock Exchange via a reverse take-over transaction.
Tiffany Thorn - CEO and Co-founder @ BiVicTrix Therapeutics Plc (LSE:BVX), a UK-based drug discovery and development company that recently listed on AIM LSE raising more than £7mn in the process. BiVicTrix is focused on leveraging clinical experience to develop a class of highly selective, next generation cancer therapeutics, whilst eliminating treatment related toxicities.